1
|
Thurner L, Fadle N, Regitz E, Preuss KD, Neumann F, Cetin O, Schormann C, Hoffmann MC, Herr C, Kheirodin P, Rixecker TM, Bals R, Muller S, Thurner B, Kessel C, Kabesch M, Bewarder M, Heyne K, Lensch C, Kos IA. Autoantibodies against SUMO1-DHX35 in long-COVID. J Transl Autoimmun 2022; 5:100171. [DOI: 10.1016/j.jtauto.2022.100171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 11/16/2022] [Indexed: 11/21/2022] Open
|
2
|
Thurner L, Hartmann S, Bewarder M, Fadle N, Regitz E, Schormann C, Quiroga N, Kemele M, Klapper W, Rosenwald A, Trümper L, Bohle RM, Nimmesgern A, Körbel C, Lascke MW, Menger MD, Barth S, Kubuschok B, Mottok A, Kaddu-Mulindwa D, Hansmann ML, Pöschel V, Held G, Murawski N, Stilgenbauer S, Neumann F, Preuss KD, Pfreundschuh M. Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica 2021; 106:2224-2232. [PMID: 32675228 PMCID: PMC8327713 DOI: 10.3324/haematol.2019.241653] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Indexed: 12/14/2022] Open
Abstract
It has been suggested that stimulation of B-cell receptors (BCR) by specific antigens plays a pathogenic role in diffuse large B-cell lymphoma (DLBCL). Here, it was the aim to screen for specific reactivities of DLBCL-BCR in the spectrum of autoantigens and antigens of infectious origin. Arsenite resistance protein 2 (Ars2) was identified as the BCR target of three of five activated B-cell type DLBCL cell lines and two of 11 primary DLBCL cases. Compared to controls, Ars2 was hypophosphorylated exclusively in cases and cell lines with Ars2-specific BCR. In a validation cohort, hypophosphorylated Ars2 was found in eight of 31 activated B-cell type DLBCL, but in only one of 20 germinal center B-cell like type DLBCL. Incubation with Ars2 induced BCR-pathway activation and increased proliferation, while an Ars2/ETA’ toxin conjugate induced killing of cell lines with Ars2-reactive BCR. Ars2 appears to play a role in a subgroup of activated B-cell-type DLBCL. Moreover, transformed DLBCL lines with Ars2-reactive BCR still showed growth advantage after incubation with Ars2. These results provide knowledge about the pathogenic role of a specific antigen stimulating the BCR pathway in DLCBL.
Collapse
Affiliation(s)
- Lorenz Thurner
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | | | - Moritz Bewarder
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | - Natalie Fadle
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | - Evi Regitz
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | | | - Natalia Quiroga
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | - Maria Kemele
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | | | - Andreas Rosenwald
- Institute of Pathology, University of Würzburg and CCC Mainfranken, Würzburg, Germany
| | - Lorenz Trümper
- Department of Hematology and Medical Oncology, University Hospital Göttingen, Germany
| | - Rainer Maria Bohle
- Saarland University Medical School, Institute of Pathology, Homburg/Saar, Germany
| | - Anna Nimmesgern
- Institute of Medical Microbiology and Hygiene, University of Saarland, Homburg, Germany
| | - Christina Körbel
- Institute for Clinical and Experimental Surgery, University of Saarland, Homburg/Saar, Germany
| | - Matthias W Lascke
- Institute for Clinical and Experimental Surgery, University of Saarland, Homburg/Saar, Germany
| | - Michael D Menger
- Institute for Clinical and Experimental Surgery, University of Saarland, Homburg/Saar, Germany
| | - Stefan Barth
- Institute for Infectious disease and Molecular Medicine, University of Cape Town, South Africa
| | - Boris Kubuschok
- Department of Internal Medicine II, Augsburg University Medical Center, Augsburg, Germany
| | - Anja Mottok
- Institute of Human Genetics, Ulm University and Ulm University Medical Center, Germany
| | | | | | - Viola Pöschel
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | - Gerhard Held
- Department of Hematology/Oncology, Westpfalzklinikum Kaiserslautern, Germany
| | - Niels Murawski
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | | | - Frank Neumann
- Saarland Medical School, Internal Medicine I, Homburg/Saar, Germany
| | | | | |
Collapse
|
3
|
Thurner L, Bewarder M, Fadle N, Regitz E, Poeschel V, Ziepert M, Schuck R, Altmeyer S, Kemele M, Bock T, Schormann C, Walter S, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Moeller P, Kim Y, Buslei R, Kaddu-Mulindwa D, Neumann F, Roemer K, Bohle R, Illerhaus G, Schorb E, Schaefer H, Hansmann M, Hartmann S, Held G, Stilgenbauer S, Murawski N, Pfreundschuh M, Preuss K. SAMD14/NEURABIN-I AS BCR-ANTIGENS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- L. Thurner
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Bewarder
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - N. Fadle
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - E. Regitz
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - V. Poeschel
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Ziepert
- Universität Leipzig; Institute for Medical Informatics, Statistics, and Epidemiology; Leipzig Germany
| | - R. Schuck
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Altmeyer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Kemele
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - T. Bock
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - C. Schormann
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Walter
- Saarland Medical School; Department of Neurology; Homburg/Saar Germany
| | - M. Szczepanowski
- University of Kiel; Institute of Pathology, Hematopathology Section and Lymph Node Registry; Kiel Germany
| | - W. Klapper
- University of Kiel; Institute of Pathology, Hematopathology Section and Lymph Node Registry; Kiel Germany
| | - C. Monoranu
- University of Würzburg; Institute of Pathology and Neuropathology; Würzburg Germany
| | - A. Rosenwald
- University of Würzburg; Institute of Pathology and Neuropathology; Würzburg Germany
| | - P. Moeller
- University of Ulm; Department of Pathology; Ulm Germany
| | - Y. Kim
- Saarland Medical school; Department of pathology; Homburg/Saar Germany
| | - R. Buslei
- SozialStiftung Bamberg; Institute of Pathology; Bamberg Germany
| | - D. Kaddu-Mulindwa
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - F. Neumann
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - K. Roemer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - R. Bohle
- Saarland Medical school; Department of pathology; Homburg/Saar Germany
| | - G. Illerhaus
- Klinikum Stuttgart; Department Hematology and Oncology; Stuttgart Germany
| | - E. Schorb
- University Medical Center Freiburg; Department of Hematology and Oncology; Freiburg Germany
| | - H. Schaefer
- University Medical Center Freiburg; Department of Hematology and Oncology; Freiburg Germany
| | - M.L. Hansmann
- Goethe University Frankfurt; Senckenberg Institute of Pathology; Frankfurt Germany
| | - S. Hartmann
- Goethe University Frankfurt; Senckenberg Institute of Pathology; Frankfurt Germany
| | - G. Held
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Stilgenbauer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - N. Murawski
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Pfreundschuh
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - K.D. Preuss
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| |
Collapse
|
4
|
Neumann F, Acker F, Schormann C, Pfreundschuh M, Bittenbring JT. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity. Cancer Immunol Immunother 2018; 67:1709-1718. [PMID: 30132083 PMCID: PMC11028244 DOI: 10.1007/s00262-018-2224-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 08/01/2018] [Indexed: 12/21/2022]
Abstract
Vitamin D3 (25-OH-D3) deficiency impairs rituximab-dependent cellular cytotoxicity and the outcome of patients with diffuse large B-cell and follicular lymphomas (DLBCL). Since the optimum 25-OH-D3 serum levels for NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) are unknown, we determined the 25-OH-D3 serum levels associated with maximum NK cell-mediated ADCC. CD20 antibody-loaded CD20+ B-cell lymphoma cell lines were cultured with NK cells and ADCC activity was determined by lactate dehydrogenase release assays. Using a newly developed formula, pre-defined 25-OH-D3 serum levels were achieved with high individual precision over a wide range. NK cells from 20 healthy individuals killed antibody-treated CD20+ lymphoma cells in a concentration- and E:T ratio-dependent manner with obinutuzumab displaying a stronger ADCC activity than rituximab. Maximum NK-cell activity and ADCC were observed at 65 ng/ml 25-OH-D3, the middle of the normal range (30-100 ng/ml). 25-OH-D3 serum levels around this range should be the target in interventional trials aiming at improving NK cell-mediated ADCC by 25-OH-D3 substitution. Lower levels do not provide significant ADCC improvements in individuals with 25-OH-D3 deficiency or insufficiency and might result in the failure of interventions with 25-OH-D3.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/pharmacology
- Antibody-Dependent Cell Cytotoxicity/immunology
- Antineoplastic Agents, Immunological/pharmacology
- Case-Control Studies
- Cholecalciferol/blood
- Cholecalciferol/immunology
- Cytotoxicity, Immunologic/immunology
- Female
- Healthy Volunteers
- Humans
- Killer Cells, Natural/immunology
- Lymphocyte Activation
- Lymphoma, Large B-Cell, Diffuse/blood
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Rituximab/pharmacology
Collapse
Affiliation(s)
- Frank Neumann
- José Carreras Center for Immuno and Gene Therapy, Saarland University, Homburg, Saarland, Germany
| | - Fabian Acker
- Department of Internal Medicine I, Saarland University Medical Center, Kirrberger Strasse 100, 66421, Homburg, Saarland, Germany
| | - Claudia Schormann
- José Carreras Center for Immuno and Gene Therapy, Saarland University, Homburg, Saarland, Germany
| | - Michael Pfreundschuh
- Department of Internal Medicine I, Saarland University Medical Center, Kirrberger Strasse 100, 66421, Homburg, Saarland, Germany
| | - Joerg Thomas Bittenbring
- Department of Internal Medicine I, Saarland University Medical Center, Kirrberger Strasse 100, 66421, Homburg, Saarland, Germany.
| |
Collapse
|
5
|
Neumann F, Pfreundschuh M, Preuss KD, Schormann C, Zwick C, Murawski N, Kubuschok B. CD4⁺ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia. Int J Cancer 2015; 137:1076-84. [PMID: 25677163 DOI: 10.1002/ijc.29478] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 02/04/2015] [Indexed: 11/11/2022]
Abstract
Hyperphosphorylated paratarg-7 (pP-7) carrier state is the strongest and most frequent molecular risk factor for MGUS, multiple myeloma (MM) and Waldenström's macroglobulinemia (WM), inherited autosomal-dominantly and, depending on the ethnic background, found in up to one third of patients with MGUS/MM. Since P-7 is the antigenic target of paraproteins that do not distinguish between wtP-7 and pP-7, we investigated CD4(+) T-cell responses in pP-7(+) patients and controls. Peptides spanning amino acids 1-35 or 4-31 containing phosphorylated or nonphosphorylated serine17 were used for stimulation. CD4(+) cells from 9/14 patients (65%) showed a pP-7 specific HLA-DR restricted response. These results demonstrate that pP-7 specific CD4(+) cells can mediate help for pP-7 specific chronic antigenic stimulation of P-7 specific B cells, which might ultimately result in the clonal evolution of a B cell into MGUS/MM/WM producing a P-7 specific paraprotein. Prerequisites for pP-7 specific stimulation of CD4(+) cells appear to be both a pP-7 carrier state and an HLA-DR subtype able to present and recognize pP-7. Our results serve as an explanation for the exclusive autoimmunogenicity of the hyperphosphorylated variant of P-7 and for the different hazard ratios of pP-7 carriers from different ethnic origins to develop MGUS/MM/WM.
Collapse
Affiliation(s)
- Frank Neumann
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Michael Pfreundschuh
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Klaus D Preuss
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Claudia Schormann
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Carsten Zwick
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Niels Murawski
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| | - Boris Kubuschok
- José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
| |
Collapse
|
6
|
Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer Immunol Immunother 2011; 60:1333-46. [PMID: 21630107 PMCID: PMC11028599 DOI: 10.1007/s00262-011-1030-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2010] [Accepted: 04/27/2011] [Indexed: 10/18/2022]
Abstract
BACKGROUND Antigen-derived HLA class I-restricted peptides can generate specific CD8(+) T-cell responses in vivo and are therefore often used as vaccines for patients with cancer. However, only occasional objective clinical responses have been reported suggesting the necessity of CD4(+) T-cell help and possibly antibodies for the induction of an effective anti-tumor immunity in vivo. The SSX2 gene encodes the cancer testis antigen (CTA) HOM-MEL-40/SSX2, which is frequently expressed in a wide spectrum of cancers. Both humoral and cellular immune responses against SSX2 have been described making SSX2 an attractive candidate for vaccine trials. METHODS SYFPEITHI algorithm was used to predict five pentadecamer peptides with a high binding probability for six selected HLA-DRB1 subtypes (*0101, *0301, *0401, *0701, *1101, *1501) which are prevalent in the Caucasian population. RESULTS Using peripheral blood cells of 13 cancer patients and 5 healthy controls, the HOM-MEL-40/SSX2-derived peptide p101-111 was identified as an epitope with dual immunogenicity for both CD4(+) helper and cytotoxic CD8(+) T cells. This epitope also reacted with anti-SSX2 antibodies in the serum of a patient with breast cancer. Most remarkably, SSX2/p101-111 simultaneously induced specific CD8, CD4, and antibody responses in vitro. CONCLUSIONS p101-111 is the first CTA-derived peptide which induces CD4(+), CD8(+), and B-cell responses in vitro. This triple-immunogenic peptide represents an attractive vaccine candidate for the induction of effective anti-tumor immunity.
Collapse
Affiliation(s)
- Frank Neumann
- José-Carreras-Center at the Department of Internal Medicine I—Build. 45.3, Saarland University Medical School, 66424 Homburg, Germany
| | - Boris Kubuschok
- José-Carreras-Center at the Department of Internal Medicine I—Build. 45.3, Saarland University Medical School, 66424 Homburg, Germany
| | - Kubilay Ertan
- Department of Gynecology and Obstetrics, Clinical Center Leverkusen GmbH, 51375 Leverkusen, Germany
| | - Claudia Schormann
- José-Carreras-Center at the Department of Internal Medicine I—Build. 45.3, Saarland University Medical School, 66424 Homburg, Germany
| | - Stefan Stevanovic
- Department of Immunology, Institute for Cell Biology, Eberhard-Karls-University, 72076 Tübingen, Germany
| | - Klaus-Dieter Preuss
- José-Carreras-Center at the Department of Internal Medicine I—Build. 45.3, Saarland University Medical School, 66424 Homburg, Germany
| | - Werner Schmidt
- Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical School, 66424 Homburg, Germany
| | - Michael Pfreundschuh
- Department of Internal Medicine I—Build. 40, Saarland University Medical School, 66424 Homburg, Germany
| |
Collapse
|
7
|
Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006; 12:1365-72. [PMID: 16489095 DOI: 10.1158/1078-0432.ccr-05-1672] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mutated p21 ras proteins (muRas) are present in approximately 90% of pancreatic adenocarcinomas and express mutants which can function as cancer-specific antigens. To evaluate the frequency and magnitude of the natural T-cell response against muRas in 19 HLA-A2-positive patients with muRas-positive pancreatic carcinomas, antigen-experienced T lymphocytes in fresh peripheral blood mononuclear cells were shown by IFN-gamma enzyme-linked immunospot using muRas peptides (5-21) that encompass both HLA class I (HLA-A2)- and class II-restricted (HLA-DRB1) epitopes. Six of 19 patients (32%) were found to have a specific T-cell response against individual mutation-specific ras(5-21) but not against other ras mutations or wild-type ras. In contrast, none of 19 healthy subjects had T cells specifically secreting IFN-gamma (P = 0.004). The T-cell response consisted of both CD8(+) and CD4(+) T cells but was dominated by CD8 T cells in three of four patients. MuRas(5-14) and muRas(6-14) were shown to specifically induce CD8(+) T-cell mediated cytotoxicity against HLA-A2-positive, muRas-bearing pancreatic carcinoma cells. The T-cell response was not correlated with prognostic or clinical variables such as tumor-node-metastasis status, stage, or survival. In conclusion, a natural T-cell response against muRas proteins that could be exploited for immunostimulatory therapeutic approaches has been shown in a significant proportion of patients with pancreatic cancer.
Collapse
Affiliation(s)
- Boris Kubuschok
- Department of Internal Medicine I , University of Saarland Medical School, Homburg/Saar, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006; 118:696-703. [PMID: 16094643 DOI: 10.1002/ijc.21352] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
To determine the expression of cancer testis (CT) genes and antibody responses in a nonselected population of patients with primary breast cancer, we investigated the composite expression of 11 CT genes by RT-PCR in fresh biopsies of 100 consecutive cases of primary breast carcinoma and by immunohistology in selected RT-PCR-positive cases. Antibody responses against 7 CT antigens were analyzed using recombinant antigen expression on yeast surface. In 98 evaluable cases, SCP-1 and SSX-4 were expressed most frequently (both 65%), followed by HOM-TES-85/CT-8 (47%), GAGE (26%), SSX-1 (20%), NY-ESO-1 (13%), MAGE-3 (11%), SSX-2 (8%), CT-10 (7%), MAGE-4 (4%) and CT-7 (1%). One CT gene was expressed by 90% of the cases; 79% expressed > or =2, 48% > or =3, 29% > or =4, 12% > or =5, 6% > or =6, 3% > or =7, 2% > or =8 and one case coexpressed 9 antigens. Of 100 serum samples screened for CT antigen-specific antibodies, antibodies against NY-ESO-1 were detected in 4 patients, against SCP-1 in 6 patients and against SSX-2 in 1 patient, while no antibodies were detected against MAGE-3, CT-7 and CT-10. Expression of CT genes or antibody responses was not correlated with clinical parameters (menopausal status, tumor size, nodal involvement, grading, histology and estrogen receptor status) or the demonstration of CT gene expression at the protein level, by immunohistology. Our results show that breast carcinomas are among the tumors with the most frequent expression of CT antigens, rendering many patients potential candidates for vaccine trials.
Collapse
MESH Headings
- Antibodies, Neoplasm/immunology
- Antibody Formation
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Antigens, Neoplasm/metabolism
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/immunology
- Biomarkers, Tumor/metabolism
- Biopsy
- Breast Neoplasms/genetics
- Breast Neoplasms/immunology
- Breast Neoplasms/metabolism
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/immunology
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/immunology
- Carcinoma, Lobular/metabolism
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Neoplasm Invasiveness/immunology
- Neoplasm Invasiveness/pathology
- Prospective Studies
- RNA, Messenger
- RNA, Neoplasm
- Receptors, Estrogen/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Testis/metabolism
Collapse
Affiliation(s)
- Axel Mischo
- Department of Internal Medicine I, University of Saarland Medical School, Homburg/Saar, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Neumann F, Wagner C, Preuss KD, Kubuschok B, Schormann C, Stevanovic S, Pfreundschuh M. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood 2005; 106:3105-13. [PMID: 16030183 DOI: 10.1182/blood-2005-04-1487] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Because of their frequent expression in a wide spectrum of malignant tumors but not in normal tissue except testis, cancer testis antigens are promising targets. However, except for HOM-TES-14/SCP1, their expression in malignant lymphomas is rare. SCP1 (synaptonemal complex protein 1) has been shown to elicit antibody responses in the autologous host, but no T-cell responses against HOM-TES-14/SCP1 have been reported. Using the SYFPEITHI algorithm, we selected peptides with a high binding affinity to major histocompatibility complex class 2 (MHC 2) molecules. The pentadecamer epitope p635-649 induced specific CD4+ T-cell responses that were shown to be restricted by HLA-DRB1*1401. The responses could be blocked by preincubation of T cells with anti-CD4 and antigen-presenting cells with anti-HLA-DR, respectively, proving the HLA-DR-restricted presentation of p635-649 and a CD4+ T-cell-mediated effector response. Responding CD4+ cells did not secrete interleukin-5 (IL-5), indicating that they belong to the T(H)1 subtype. The natural processing and presentation of p635-649 were demonstrated by pulsing autologous and allogeneic dendritic cells with a protein fragment covering p635-649. Thus, p635-649 is the first HOM-TES-14/SCP1-derived epitope to fulfill all prerequisites for use as a peptide vaccine in patients with HOM-TES-14/SCP1-expressing tumors, which is the case in two thirds of peripheral T-cell lymphomas.
Collapse
Affiliation(s)
- Frank Neumann
- Medizinische Klinik I, Saarland University Medical School, D-66421 Homburg/Saar, Germany
| | | | | | | | | | | | | |
Collapse
|
10
|
Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer 2004; 112:661-8. [PMID: 15382048 DOI: 10.1002/ijc.20461] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The SSX2 gene encodes the tumor-specific antigen HOM-MEL-40/SSX2 expressed in a broad spectrum of tumors of different origin, against which humoral and CD8+ T-cell-mediated MHC-I-restricted responses have been demonstrated. Searching for promiscuous MHC-II-restricted peptides that might be suitable as a CD4+ stimulating vaccine for many patients, we used the SYFPEITHI algorithm and identified a HOM-MEL-40/SSX2-derived pentadecamer epitope (p45-59) that induced specific CD4+ T-cell responses restricted by the HLA-DRB1 subtypes *0701, *1101 and *1302 that have a cumulative prevalence of approximately 25% in the Caucasian population. The CD4+-mediated response against p45-59 and its DR restriction was demonstrated by inhibition with anti-CD4 and HLA-DR antibodies, respectively, and by blocking experiments using HLA-specific antibodies. The natural processing and presentation of p45-59 was demonstrated by recognition of the SSX2+ melanoma cell line Me 275 as well as autologous and allogeneic dendritic cells pulsed with whole-protein SSX2 by T cells with specificity for p45-59. p45-59 was able to induce responses in 3/6 breast cancer patients and 1/5 healthy controls. No correlation was found between CD4+ T-cell responses against p45-59 reactivity and anti-SSX2 antibody titers in the serum of patients, suggesting that CD4+ and B-cell responses are regulated independently. p45-59 holds promise as a broadly applicable peptide vaccine for patients with SSX2-positive neoplasms.
Collapse
Affiliation(s)
- Frank Neumann
- Medizinische Klinik I, Saarland University Medical School, Homburg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|